{"hands_on_practices": [{"introduction": "To understand the impact of plasma protein binding, we must first quantify the \"binding landscape\" itself. This foundational exercise involves calculating the total concentration of available binding sites based on the physiological concentrations of major binding proteins. By treating each protein molecule as a single binding unit, you will develop a tangible sense of the plasma's capacity to sequester drugs, a crucial first step before exploring more complex binding phenomena. [@problem_id:4580817]", "problem": "A small-molecule drug exhibits noncovalent, reversible binding to plasma macromolecules. In a conceptual regime where each macromolecular species contributes a single, independent binding site per molecule or particle, the total number of binding sites available at saturation is determined entirely by the stoichiometric count of macromolecular binding units present in plasma. Starting only from the definition of molar concentration and the stoichiometry of binding sites, derive the expression for the maximum binding capacity when each macromolecule contributes one site, and then evaluate it numerically for a typical human plasma composition.\n\nAssume the following scientifically plausible, representative concentrations at physiological conditions:\n- Serum albumin: $0.60\\,\\mathrm{mM}$.\n- Alpha-1-acid glycoprotein (AAG): $20\\,\\mu\\mathrm{M}$.\n- High-density lipoprotein (HDL) particle concentration: $30\\,\\mu\\mathrm{M}$.\n- Low-density lipoprotein (LDL) particle concentration: $1.2\\,\\mu\\mathrm{M}$.\n- Very-low-density lipoprotein (VLDL) particle concentration: $0.10\\,\\mu\\mathrm{M}$.\n\nTreat each albumin molecule, each AAG molecule, and each lipoprotein particle as a single binding unit with one drug-binding site. Using these values, compute the total maximum binding capacity for the drug in plasma, expressed as a concentration of sites in $\\mu\\mathrm{mol}/\\mathrm{L}$.\n\nRound your final answer to four significant figures and express it in $\\mu\\mathrm{mol}/\\mathrm{L}$.", "solution": "The user has provided a problem statement that must first be validated for scientific soundness, completeness, and objectivity before a solution is attempted.\n\n### Step 1: Extract Givens\n- **Binding characteristics**: Noncovalent, reversible binding of a small-molecule drug to plasma macromolecules.\n- **Model assumption**: Each macromolecular species contributes a single, independent binding site per molecule or particle ($n_i = 1$).\n- **Definition**: The total number of binding sites available at saturation (maximum binding capacity, $B_{max}$) is determined by the stoichiometric count of macromolecular binding units.\n- **Task**: Derive the expression for the maximum binding capacity and evaluate it numerically.\n- **Macromolecule concentrations**:\n  - Serum albumin, $C_{Alb}$: $0.60\\,\\mathrm{mM}$\n  - Alpha-1-acid glycoprotein (AAG), $C_{AAG}$: $20\\,\\mu\\mathrm{M}$\n  - High-density lipoprotein (HDL), $C_{HDL}$: $30\\,\\mu\\mathrm{M}$\n  - Low-density lipoprotein (LDL), $C_{LDL}$: $1.2\\,\\mu\\mathrm{M}$\n  - Very-low-density lipoprotein (VLDL), $C_{VLDL}$: $0.10\\,\\mu\\mathrm{M}$\n- **Stoichiometry assumption**: Each albumin molecule, AAG molecule, and lipoprotein particle is treated as a single binding unit with one site.\n- **Required output**: Total maximum binding capacity expressed in $\\mu\\mathrm{mol}/\\mathrm{L}$, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem is well-grounded in the principles of clinical pharmacology and pharmacokinetics. Plasma protein binding is a fundamental concept, and the macromolecules listed (albumin, AAG, lipoproteins) are the primary entities responsible for this phenomenon. The provided concentrations are physiologically realistic for a typical human. The assumption of a single binding site per macromolecule is a common simplification used in introductory models to establish the core concept of binding capacity. This does not render the problem scientifically unsound, as it is a clearly stated and constrained assumption for a conceptual problem.\n- **Well-Posed**: The problem is well-posed. It provides all necessary data (concentrations of binding species) and a clear, simple stoichiometric model ($1$ site per molecule/particle) to calculate a unique solution. The objective is clearly defined: calculate the total concentration of binding sites.\n- **Objective**: The problem is stated in objective, quantitative, and precise scientific language. It is free from subjective claims or ambiguity.\n- **Completeness and Consistency**: The problem is self-contained. All necessary concentrations are provided. The units are consistent and interconvertible ($\\mathrm{mM}$ and $\\mu\\mathrm{M}$). There are no contradictions.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is scientifically sound, well-posed, and complete. A solution will be derived and calculated as requested.\n\n### Solution Derivation\nThe maximum binding capacity, which we shall denote as $[S_{total}]$, is defined as the total molar concentration of available binding sites in the plasma. This capacity represents the upper limit of drug concentration that can be bound, which occurs when all binding sites are saturated.\n\nBased on the definition of molar concentration and stoichiometry, the concentration of binding sites, $[S_i]$, contributed by a specific macromolecular species $i$ is the product of the molar concentration of that species, $C_i$, and the number of binding sites per molecule or particle of that species, $n_i$.\n$$[S_i] = n_i \\times C_i$$\n\nThe total maximum binding capacity is the sum of the binding site concentrations from all contributing species.\n$$[S_{total}] = \\sum_i [S_i] = \\sum_i (n_i C_i)$$\n\nThe problem states that for the purpose of this conceptual regime, we are to assume that each macromolecule or lipoprotein particle contributes exactly one binding site. Therefore, for all species $i$ (albumin, AAG, HDL, LDL, VLDL), the stoichiometry is $n_i = 1$.\nThe expression for total binding capacity simplifies to the sum of the concentrations of the macromolecular species themselves:\n$$[S_{total}] = C_{Alb} + C_{AAG} + C_{HDL} + C_{LDL} + C_{VLDL}$$\n\nNow, we must evaluate this expression numerically. The final answer is required in units of $\\mu\\mathrm{mol}/\\mathrm{L}$, which is equivalent to micromolar ($\\mu\\mathrm{M}$). We must first convert all given concentrations to these units.\n\nThe given concentrations are:\n- $C_{Alb} = 0.60\\,\\mathrm{mM}$\n- $C_{AAG} = 20\\,\\mu\\mathrm{M}$\n- $C_{HDL} = 30\\,\\mu\\mathrm{M}$\n- $C_{LDL} = 1.2\\,\\mu\\mathrm{M}$\n- $C_{VLDL} = 0.10\\,\\mu\\mathrm{M}$\n\nThe concentration of albumin must be converted from millimolar ($\\mathrm{mM}$) to micromolar ($\\mu\\mathrm{M}$). The conversion factor is $1\\,\\mathrm{mM} = 1000\\,\\mu\\mathrm{M}$.\n$$C_{Alb} = 0.60\\,\\mathrm{mM} \\times \\frac{1000\\,\\mu\\mathrm{M}}{1\\,\\mathrm{mM}} = 600\\,\\mu\\mathrm{M}$$\n\nThe other concentrations are already in the required units. Now we can sum the concentrations to find the total concentration of binding sites.\n$$[S_{total}] = 600\\,\\mu\\mathrm{M} + 20\\,\\mu\\mathrm{M} + 30\\,\\mu\\mathrm{M} + 1.2\\,\\mu\\mathrm{M} + 0.10\\,\\mu\\mathrm{M}$$\n$$[S_{total}] = (600 + 20 + 30 + 1.2 + 0.10)\\,\\mu\\mathrm{M}$$\n$$[S_{total}] = 651.3\\,\\mu\\mathrm{M}$$\n\nThe result is $651.3\\,\\mu\\mathrm{M}$. In the requested units of $\\mu\\mathrm{mol}/\\mathrm{L}$, this is $651.3\\,\\mu\\mathrm{mol}/\\mathrm{L}$. The problem asks for the answer to be rounded to four significant figures. The calculated value $651.3$ already has precisely four significant figures. Therefore, no further rounding is necessary.", "answer": "$$\\boxed{651.3}$$", "id": "4580817"}, {"introduction": "In clinical practice, patients are often treated with multiple drugs simultaneously, creating a scenario where different molecules may compete for the same plasma protein binding sites. This practice challenges you to derive the governing equations for such a competitive system from first principles. By applying the law of mass action to a two-drug, single-site model, you will build a mathematical expression that quantifies how the presence of a competing drug alters the unbound fraction of another, revealing the fundamental mechanism of many protein binding-related drug-drug interactions. [@problem_id:4580773]", "problem": "Two drugs $A$ and $B$ competitively bind to the same single class of non-cooperative binding sites on albumin. Let $P$ denote the concentration of unoccupied binding sites, $P_t$ the total concentration of binding sites, $[AP]$ and $[BP]$ the concentrations of the respective drugâ€“albumin complexes, and $C_{u,A}$ and $C_{u,B}$ the free (unbound) plasma concentrations of $A$ and $B$. The binding equilibria obey the law of mass action with dissociation constants $K_{d,A}$ and $K_{d,B}$, respectively. Assume instantaneous equilibrium and that each site can be occupied by at most one ligand ($A$ or $B$), with no other interactions.\n\nStarting only from the law of mass action and the conservation of binding sites, derive the competitive binding relations and obtain an explicit closed-form expression for the fraction unbound in plasma (f_{u,p}) of drug $A$, denoted $f_{u,p,A}$, defined as the ratio of the free concentration of $A$ to its total plasma concentration. Express your final answer solely as a function of $K_{d,A}$, $K_{d,B}$, $P_t$, $C_{u,A}$, and $C_{u,B}$. Provide only the final analytic expression for $f_{u,p,A}$. No numerical evaluation is required, and no units should be included in the final expression.", "solution": "The problem is first validated against the required criteria.\n\n### Step 1: Extract Givens\n-   Two drugs, $A$ and $B$, competitively bind to a single class of non-cooperative binding sites on albumin.\n-   Variables:\n    -   $P$: concentration of unoccupied binding sites.\n    -   $P_t$: total concentration of binding sites.\n    -   $[AP]$: concentration of drug $A$-albumin complex.\n    -   $[BP]$: concentration of drug $B$-albumin complex.\n    -   $C_{u,A}$: free (unbound) plasma concentration of drug $A$.\n    -   $C_{u,B}$: free (unbound) plasma concentration of drug $B$.\n-   Constants:\n    -   $K_{d,A}$: dissociation constant for drug $A$.\n    -   $K_{d,B}$: dissociation constant for drug $B$.\n-   Principles  Assumptions:\n    -   The binding equilibria obey the law of mass action.\n    -   Equilibrium is assumed to be instantaneous.\n    -   Each site can be occupied by at most one ligand ($A$ or $B$).\n    -   No other interactions occur.\n-   Objective:\n    -   Derive an explicit closed-form expression for the fraction unbound in plasma of drug $A$, denoted $f_{u,p,A}$.\n-   Definition:\n    -   $f_{u,p,A}$ is the ratio of the free concentration of $A$ to its total plasma concentration.\n-   Constraint:\n    -   The final expression must be a function of only $K_{d,A}$, $K_{d,B}$, $P_t$, $C_{u,A}$, and $C_{u,B}$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is scientifically grounded, rooted in the fundamental principles of chemical equilibrium (law of mass action) as applied to pharmacokinetics (protein binding). The setup is a standard, well-characterized model of competitive ligand binding. All terms are defined formally and objectively. The problem is self-contained, providing all necessary definitions, constants, and relationships to derive the desired quantity. There are no contradictions, ambiguities, or scientifically unsound premises. The problem is well-posed and a unique analytical solution is expected to exist.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. A full derivation will be provided.\n\nThe derivation begins from the fundamental principles outlined in the problem statement. The target quantity is the fraction unbound of drug $A$ in plasma, $f_{u,p,A}$. This is defined as the ratio of the free drug concentration, $C_{u,A}$, to the total drug concentration, $C_{t,A}$. The total concentration is the sum of the free and bound concentrations:\n\n$$\nC_{t,A} = C_{u,A} + [AP]\n$$\n\nTherefore, the expression for $f_{u,p,A}$ is:\n\n$$\nf_{u,p,A} = \\frac{C_{u,A}}{C_{t,A}} = \\frac{C_{u,A}}{C_{u,A} + [AP]}\n$$\n\nTo find an expression for $f_{u,p,A}$ in terms of the specified variables, we must first find an expression for the concentration of the bound complex, $[AP]$.\n\nThe binding equilibria for drugs $A$ and $B$ are described by the law of mass action via their respective dissociation constants, $K_{d,A}$ and $K_{d,B}$.\n\nFor the equilibrium $A + P \\rightleftharpoons AP$, the dissociation constant is:\n$$\nK_{d,A} = \\frac{C_{u,A} \\cdot P}{[AP]}\n$$\nRearranging this equation to solve for $[AP]$ gives:\n$$\n[AP] = \\frac{C_{u,A} \\cdot P}{K_{d,A}} \\quad (1)\n$$\n\nSimilarly, for the equilibrium $B + P \\rightleftharpoons BP$, the dissociation constant is:\n$$\nK_{d,B} = \\frac{C_{u,B} \\cdot P}{[BP]}\n$$\nRearranging for $[BP]$ gives:\n$$\n[BP] = \\frac{C_{u,B} \\cdot P}{K_{d,B}} \\quad (2)\n$$\n\nThe total concentration of binding sites, $P_t$, is conserved. It is the sum of the concentration of unoccupied sites ($P$), sites occupied by drug $A$ ($[AP]$), and sites occupied by drug $B$ ($[BP]$).\n$$\nP_t = P + [AP] + [BP] \\quad (3)\n$$\n\nTo solve for the unknown concentration of free sites, $P$, we substitute equations $(1)$ and $(2)$ into equation $(3)$:\n$$\nP_t = P + \\frac{C_{u,A} \\cdot P}{K_{d,A}} + \\frac{C_{u,B} \\cdot P}{K_{d,B}}\n$$\n\nWe can factor out $P$ from the right-hand side:\n$$\nP_t = P \\left( 1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}} \\right)\n$$\n\nSolving for $P$ yields:\n$$\nP = \\frac{P_t}{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}} \\quad (4)\n$$\nThis expression gives the concentration of free binding sites in terms of known or specified quantities.\n\nNow we can determine $[AP]$. Substitute the expression for $P$ from equation $(4)$ into equation $(1)$:\n$$\n[AP] = \\frac{C_{u,A}}{K_{d,A}} \\cdot \\left( \\frac{P_t}{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}} \\right)\n$$\n$$\n[AP] = \\frac{\\frac{P_t \\cdot C_{u,A}}{K_{d,A}}}{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}} \\quad (5)\n$$\n\nWith this expression for $[AP]$, we can now formulate $f_{u,p,A}$. It is algebraically convenient to first find the reciprocal, $\\frac{1}{f_{u,p,A}}$:\n$$\n\\frac{1}{f_{u,p,A}} = \\frac{C_{u,A} + [AP]}{C_{u,A}} = 1 + \\frac{[AP]}{C_{u,A}}\n$$\nSubstitute equation $(5)$ into this relationship:\n$$\n\\frac{1}{f_{u,p,A}} = 1 + \\frac{1}{C_{u,A}} \\left( \\frac{\\frac{P_t \\cdot C_{u,A}}{K_{d,A}}}{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}} \\right)\n$$\nThe term $C_{u,A}$ in the numerator and the outer factor cancel:\n$$\n\\frac{1}{f_{u,p,A}} = 1 + \\frac{\\frac{P_t}{K_{d,A}}}{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}}\n$$\nCombine the terms on the right-hand side over a common denominator:\n$$\n\\frac{1}{f_{u,p,A}} = \\frac{\\left( 1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}} \\right) + \\frac{P_t}{K_{d,A}}}{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}}\n$$\nGroup terms in the numerator:\n$$\n\\frac{1}{f_{u,p,A}} = \\frac{1 + \\frac{C_{u,A} + P_t}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}}{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}}\n$$\nFinally, taking the reciprocal gives the desired expression for $f_{u,p,A}$:\n$$\nf_{u,p,A} = \\frac{1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}}{1 + \\frac{C_{u,A} + P_t}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}}}\n$$\nTo obtain a form free of nested fractions, we can multiply the numerator and denominator by $K_{d,A}$:\n$$\nf_{u,p,A} = \\frac{K_{d,A} \\left( 1 + \\frac{C_{u,A}}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}} \\right)}{K_{d,A} \\left( 1 + \\frac{C_{u,A} + P_t}{K_{d,A}} + \\frac{C_{u,B}}{K_{d,B}} \\right)} = \\frac{K_{d,A} + C_{u,A} + C_{u,B}\\frac{K_{d,A}}{K_{d,B}}}{K_{d,A} + (C_{u,A} + P_t) + C_{u,B}\\frac{K_{d,A}}{K_{d,B}}}\n$$\nRearranging the denominator for clarity gives the final closed-form expression:\n$$\nf_{u,p,A} = \\frac{K_{d,A} + C_{u,A} + \\frac{K_{d,A}}{K_{d,B}}C_{u,B}}{K_{d,A} + P_t + C_{u,A} + \\frac{K_{d,A}}{K_{d,B}}C_{u,B}}\n$$\nThis expression is solely a function of $K_{d,A}$, $K_{d,B}$, $P_t$, $C_{u,A}$, and $C_{u,B}$, as required.", "answer": "$$\\boxed{\\frac{K_{d,A} + C_{u,A} + \\frac{K_{d,A}}{K_{d,B}}C_{u,B}}{K_{d,A} + P_t + C_{u,A} + \\frac{K_{d,A}}{K_{d,B}}C_{u,B}}}$$", "id": "4580773"}, {"introduction": "The principles of plasma protein binding have direct and critical implications for patient care, especially when physiological conditions change. This problem simulates a common clinical scenario: adjusting a drug regimen for a patient with hypoalbuminemia, a condition that reduces the number of available binding sites for albumin-bound drugs. By working through this case, you will apply the free drug hypothesis to calculate the necessary dose adjustment to maintain a target therapeutic free concentration, demonstrating how changes in binding directly influence a drug's pharmacokinetics and the dosing strategy required for efficacy and safety. [@problem_id:4580864]", "problem": "A single intravenous (IV) bolus dose of a low-extraction hepatically eliminated drug is administered every $\\tau = 12\\,\\mathrm{h}$ to a patient with hypoalbuminemia. The target is to achieve a steady-state free (unbound) trough plasma concentration $C_{\\text{free,trough,target}} = 0.5\\,\\mathrm{mg}\\,\\mathrm{L}^{-1}$ just before each subsequent dose. The drug exhibits linear one-compartment pharmacokinetics with immediate distribution after the bolus and first-order elimination. Plasma protein binding is described by the unbound fraction in plasma $f_{u,p}$, which has increased from a baseline value $f_{u,p,0} = 0.05$ to $f_{u,p,1} = 0.15$ due to hypoalbuminemia.\n\nAssume hepatic clearance follows the well-stirred model and that the drug is low-extraction at both binding states so that hepatic clearance can be approximated by $Cl \\approx f_{u,p}\\,CL_{\\text{int}}$, where $CL_{\\text{int}}$ is the intrinsic hepatic clearance. Let $CL_{\\text{int}} = 30\\,\\mathrm{L}\\,\\mathrm{h}^{-1}$. The steady-state volume of distribution is $V = 40\\,\\mathrm{L}$ and is dominated by tissue binding, which is unchanged by hypoalbuminemia. Bioavailability is $F = 1$ by the IV route.\n\nUsing these assumptions and first principles of first-order elimination and geometric accumulation at steady state, determine the single-dose maintenance dose $D$ (per administration) required to achieve $C_{\\text{free,trough,target}}$ under the new binding condition $f_{u,p,1}$. Express your final maintenance dose in $\\mathrm{mg}$ and round to three significant figures.", "solution": "The objective is to determine the maintenance dose, $D$, required to achieve a target steady-state free trough plasma concentration, $C_{\\text{free,trough,target}}$, for a drug administered as an intravenous (IV) bolus every $\\tau$ hours. The patient has hypoalbuminemia, which has altered the drug's plasma protein binding.\n\nThe fundamental principles governing this problem are based on a one-compartment pharmacokinetic model with first-order elimination after IV bolus administration. The concentration of a drug at steady-state fluctuates between a maximum ($C_{\\text{ss,max}}$) and a minimum, or trough ($C_{\\text{ss,trough}}$), level. For a multiple IV bolus regimen, the total trough plasma concentration at steady state is given by:\n$$C_{\\text{ss,trough}} = \\frac{D}{V} \\frac{\\exp(-k_e \\tau)}{1 - \\exp(-k_e \\tau)}$$\nwhere $D$ is the dose, $V$ is the volume of distribution, $k_e$ is the first-order elimination rate constant, and $\\tau$ is the dosing interval. This equation can be rewritten as:\n$$C_{\\text{ss,trough}} = \\frac{D}{V} \\frac{1}{\\exp(k_e \\tau) - 1}$$\nThe problem requires achieving a target *free* concentration. The relationship between total concentration ($C$) and free concentration ($C_{\\text{free}}$) is defined by the unbound fraction in plasma, $f_{u,p}$:\n$$C_{\\text{free}} = f_{u,p} \\times C$$\nTherefore, the target total trough concentration, $C_{\\text{ss,trough,target}}$, is:\n$$C_{\\text{ss,trough,target}} = \\frac{C_{\\text{free,trough,target}}}{f_{u,p,1}}$$\nwhere $f_{u,p,1}$ is the unbound fraction in the patient's current state of hypoalbuminemia.\n\nTo solve for the dose $D$, we must first determine the pharmacokinetic parameters under the new condition.\nThe givens are:\n- Target free trough concentration: $C_{\\text{free,trough,target}} = 0.5\\,\\mathrm{mg}\\,\\mathrm{L}^{-1}$\n- Dosing interval: $\\tau = 12\\,\\mathrm{h}$\n- New unbound fraction: $f_{u,p,1} = 0.15$\n- Intrinsic hepatic clearance: $CL_{\\text{int}} = 30\\,\\mathrm{L}\\,\\mathrm{h}^{-1}$\n- Volume of distribution: $V = 40\\,\\mathrm{L}$ (assumed constant)\n\nFirst, we calculate the hepatic clearance ($Cl_1$) under the new binding condition. For a low-extraction drug, clearance is approximated by the product of the unbound fraction and the intrinsic clearance:\n$$Cl_1 = f_{u,p,1} \\times CL_{\\text{int}}$$\nSubstituting the given values:\n$$Cl_1 = 0.15 \\times 30\\,\\mathrm{L}\\,\\mathrm{h}^{-1} = 4.5\\,\\mathrm{L}\\,\\mathrm{h}^{-1}$$\n\nNext, we calculate the elimination rate constant ($k_{e,1}$) corresponding to this new clearance. The elimination rate constant is the ratio of clearance to the volume of distribution:\n$$k_{e,1} = \\frac{Cl_1}{V}$$\nSubstituting the calculated clearance and the given volume of distribution:\n$$k_{e,1} = \\frac{4.5\\,\\mathrm{L}\\,\\mathrm{h}^{-1}}{40\\,\\mathrm{L}} = 0.1125\\,\\mathrm{h}^{-1}$$\n\nNow we can set up the equation to solve for the dose $D$. We equate the target total trough concentration with the formula for steady-state trough concentration:\n$$\\frac{C_{\\text{free,trough,target}}}{f_{u,p,1}} = \\frac{D}{V} \\frac{1}{\\exp(k_{e,1} \\tau) - 1}$$\nRearranging this equation to solve for $D$:\n$$D = \\frac{C_{\\text{free,trough,target}} \\times V}{f_{u,p,1}} \\left( \\exp(k_{e,1} \\tau) - 1 \\right)$$\n\nNow, we substitute all the known numerical values into this equation. First, we compute the exponent term:\n$$k_{e,1} \\tau = 0.1125\\,\\mathrm{h}^{-1} \\times 12\\,\\mathrm{h} = 1.35$$\nNow, substitute this and the other values into the equation for $D$:\n$$D = \\frac{0.5\\,\\mathrm{mg}\\,\\mathrm{L}^{-1} \\times 40\\,\\mathrm{L}}{0.15} \\left( \\exp(1.35) - 1 \\right)$$\n$$D = \\frac{20\\,\\mathrm{mg}}{0.15} \\left( \\exp(1.35) - 1 \\right)$$\n$$D = \\frac{400}{3}\\,\\mathrm{mg} \\left( \\exp(1.35) - 1 \\right)$$\nUsing a calculator for the numerical value:\n$$\\exp(1.35) \\approx 3.8574255$$\n$$D \\approx \\frac{400}{3} (3.8574255 - 1) = \\frac{400}{3} (2.8574255)$$\n$$D \\approx 133.333... \\times 2.8574255 \\approx 380.99007\\,\\mathrm{mg}$$\nThe problem requires the final answer to be rounded to three significant figures.\n$$D \\approx 381\\,\\mathrm{mg}$$\nThis is the required maintenance dose to be administered every $12$ hours to achieve the target free trough concentration.", "answer": "$$\\boxed{381}$$", "id": "4580864"}]}